The Goldman Sachs Group Inc
(NYSE:GSpA.PFD)
$
24.07
0.09 (0.38%)
Market Cap: 98.68 Bil
Enterprise Value: 259.04 Bil
PE Ratio: 17.67
PB Ratio: 1.75
GF Score: 76/100 
Kronos Bio, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-15-2023 10:40 AM Transcript
Jun 15, 2023 / 05:40PM GMT
Release Date Price:
$20.27
(+0.30%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Great. Good morning, everyone. Thanks for joining us. Really pleased to have with us the Kronos team. We have Norbert Bischofberger, President and CEO; Yasir Al-Wakeel, CFO and Head of Corporate Development; and Jorge DiMartino...
Charles Lin
Kronos Bio, Inc. - SVP of Biology
I'm Charles.
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Actually, Charles. sorry.
Charles Lin
Kronos Bio, Inc. - SVP of Biology
Jorge couldn't make it.
Questions & Answers
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Yes. Yes. Yes. So maybe to start here. KB-0742, your CDK inhibitor, is the first molecule to emerge from your platform. Can you start by walking through the key takeaways for the first -- from the first data release that you provided as well as the rationale for your Phase II dose selection?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers